KOL

Tonix Pharmaceuticals Announces KOL Webinar to Discuss Positive Phase 3 Fibromyalgia Data, Sponsored by A.G.P.

Retrieved on: 
Thursday, January 25, 2024
Fibromyalgia, Psychiatry, KOL, Behavioral neuroscience, University, University of Cincinnati

CHATHAM, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced a key opinion leader (KOL) webinar to discuss the positive Phase 3 data of TNX-102 SL for the management of fibromyalgia.

Key Points: 
  • CHATHAM, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced a key opinion leader (KOL) webinar to discuss the positive Phase 3 data of TNX-102 SL for the management of fibromyalgia.
  • The webinar will feature two esteemed thought leaders in the field of fibromyalgia and will be hosted by Alliance Global Partners.
  • Lesley Arnold, M.D., Professor of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine

SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa

Retrieved on: 
Wednesday, January 24, 2024
Data monitoring committee, Patient, RP, DSMB, PDE6A, Geographic atrophy, Retina, Mutation, IND, Epistasis, Disease, Paratriathlon, Safety, PDE6B, Investigational New Drug, KOL, RHO, Retinitis pigmentosa, Part Two, RCD, Pharmaceutical industry

The trial has now progressed to the final dose cohort of the dose-escalation phase (Part 1).

Key Points: 
  • The trial has now progressed to the final dose cohort of the dose-escalation phase (Part 1).
  • SPVN06 is a breakthrough gene therapy approach aimed at stopping or slowing disease progression in patients affected by rod-cone dystrophy, (RCD), regardless of their genetic background.
  • SparingVision is initially focusing on mid-stage RP, one of the leading inherited causes of blindness globally.
  • This progress of the PRODYGY trial to the third cohort at the highest dose of SPVN06 follows an earlier positive recommendation from the DSMB to dose the second cohort at the medium dose in August 2023.

Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024

Retrieved on: 
Wednesday, January 24, 2024
Pediatrics, Northwestern University, Patient, Associate, UC, Personalized medicine, Nutrition, Euronext Paris, Division, Hepatology, Therapy, Ulcerative colitis, KOL, EST, Pharmaceutical industry

The event will feature Marla Dubinsky, MD, and Parambir Dulai, MD.

Key Points: 
  • The event will feature Marla Dubinsky, MD, and Parambir Dulai, MD.
  • Along with Abivax’s management, they will be discussing the unmet medical need and current treatment landscape for patients suffering from ulcerative colitis (UC).
  • She is also Chief of the Division of Pediatric GI and Nutrition at the Mount Sinai Kravis Children’s Hospital.
  • He serves as the Director of GI Clinical Trials and Precision Medicine, as well as Director of the Digestive Health Foundation Biorepository.

ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024

Retrieved on: 
Friday, January 19, 2024
Vall d'Hebron University Hospital, Teaching hospital, Borderline personality disorder, Yale school, BPD, Yale School of Medicine, MD, Vall, Genomics, Webcast, Doctor of Philosophy, KOL, Phase

To register for the event, click here .

Key Points: 
  • To register for the event, click here .
  • The event will feature a brief review of the topline results of the Phase IIb PORTICO study, then a discussion with:
    KOL Marc Ferrer, MD, PhD (Vall d'Hebron University Hospital), PORTICO E.U.
  • KOL Sarah Fineberg, MD, PhD (Yale School of Medicine), a Psychiatrist not involved with PORTICO to provide an independent clinician’s perspective on the potential clinical and real-world implications for the results.
  • A replay of the webcast will be available on the company’s website after the event.

PharmaScroll Unveils Groundbreaking Expansion of Key Opinion Leader Database: Empowering Pharmaceutical Industry with Cutting-Edge Market Insights

Retrieved on: 
Monday, January 29, 2024
KOL, Publication, Research, Database, Social media, Expansion

HYDERABAD, India, Jan. 29, 2024 /PRNewswire/ -- PharmaScroll, a renowned market research and business analytics company, proudly announces expansion for its Key Opinion Leader (KOL) Database, TreasureTell .

Key Points: 
  • HYDERABAD, India, Jan. 29, 2024 /PRNewswire/ -- PharmaScroll, a renowned market research and business analytics company, proudly announces expansion for its Key Opinion Leader (KOL) Database, TreasureTell .
  • This groundbreaking enhancement is set to revolutionize the way pharmaceutical companies identify and engage with key opinion leaders (KOLs), enabling them to make informed decisions and drive innovation in the industry.
  • PharmaScroll has earned a sterling reputation as a trusted partner for the pharmaceutical sector, providing unparalleled market intelligence and strategic guidance.
  • "We are thrilled to introduce the expanded KOL Database, a game-changer for the pharmaceutical industry," said Sahil Singla, Director of PharmaScroll.

Alucio™ Makes Major Strides, Finishing Record Year in 2023

Retrieved on: 
Tuesday, January 16, 2024
Artificial intelligence, Research, SAN, ARR, HCP, CLM, Market access, KOL, Machine learning, Medical science liaison

SAN FRANCISCO, Jan. 16, 2024 /PRNewswire-PRWeb/ -- Alucio ™, a fast-growing provider of cloud-based software for the life sciences industry, delivered noteworthy results in 2023, and continued to deepen and extend Beacon's scientific exchange capabilities for users. Beacon, the company's flagship product, is a modern content activation and HCP engagement platform built specifically for Medical Science Liaisons (MSLs), Medical Affairs professionals, and Market Access teams.

Key Points: 
  • "We are very proud of what we were able to achieve as an organization in 2023.
  • In fact, Alucio achieved 100% customer retention in 2023 with all clients remaining active and referenceable.
  • "We are very proud of what we were able to achieve as an organization in 2023.
  • "We'll continue to innovate and work to delight our customers in 2024 to further sustain our success."

Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan

Retrieved on: 
Monday, January 8, 2024
EOS, Partnership, ACON, Physician, Biomarker, Pain, Software as a service, Surgeon, CO, LOI, Spine, Patient, Algorithm, ATEC, KOL, Pharmaceutical industry

BROOMFIELD, CO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it has executed a strategic partnership agreement solidifying the previously signed non-binding Letter of Intent (“LOI”) with Alphatec Spine, Inc., the wholly owned operating subsidiary of Alphatec Holdings, Inc. (Nasdaq: ATEC).

Key Points: 
  • That platform will be designed to improve clinical outcomes, while reducing overall procedural costs for patients with chronic low back pain (cLBP).
  • The agreement memorializes a multi-step strategic partnership in which ATEC and Aclarion have committed to work together to identify key opinion leader (KOL) surgeons to evaluate the Nociscan technology.
  • As positive synergies emerge, ATEC and Aclarion intend to co-market Nociscan in targeted markets.
  • In exchange for select access to ATEC’s surgeon network for the evaluation and advancement of Nociscan, Aclarion has agreed to provide ATEC with certain exclusive distribution rights to include Nociscan as part of an integrated procedural solution.

MiaoZhen Academy of Marketing Science: China's marketing investment is expected to increase by 11% in 2024

Retrieved on: 
Thursday, January 4, 2024
Marketing, Digital, Partnership, Health, M360, Drink, Artificial intelligence, Beauty, Science, GDMS, Food, Advertising, Social media, Growth, Creativity, ROI, KOL, Communication

BEIJING, Jan. 4, 2024 /PRNewswire/ -- On December 20th, the China Marketing Science Industry-Academia Collaboration Platform, MiaoZhen Academy of Marketing Science, in partnership with the Global Digital Marketing Summit (GDMS) and the M360, jointly released the "2024 China Digital Marketing Trends Report".

Key Points: 
  • BEIJING, Jan. 4, 2024 /PRNewswire/ -- On December 20th, the China Marketing Science Industry-Academia Collaboration Platform, MiaoZhen Academy of Marketing Science, in partnership with the Global Digital Marketing Summit (GDMS) and the M360, jointly released the "2024 China Digital Marketing Trends Report".
  • In line with the overall marketing growth rate, the expected growth rate for social media marketing in China in 2024 has also declined to 13%.
  • KOL (Key Opinion Leader) marketing remains a focus of social media investment, with 71% of advertisers indicating their intention to engage in KOL marketing.
  • Additionally, 55% of advertisers plan to increase their investment in mobile internet marketing, while 37% plan to increase their investment in outdoor advertising.

MiaoZhen Academy of Marketing Science: China's marketing investment is expected to increase by 11% in 2024

Retrieved on: 
Thursday, January 4, 2024
Marketing, Digital, Partnership, Health, M360, Drink, Artificial intelligence, Beauty, Science, GDMS, Food, Advertising, Social media, Growth, Creativity, ROI, KOL, Communication

BEIJING, Jan. 4, 2024 /PRNewswire/ -- On December 20th, the China Marketing Science Industry-Academia Collaboration Platform, MiaoZhen Academy of Marketing Science, in partnership with the Global Digital Marketing Summit (GDMS) and the M360, jointly released the "2024 China Digital Marketing Trends Report".

Key Points: 
  • BEIJING, Jan. 4, 2024 /PRNewswire/ -- On December 20th, the China Marketing Science Industry-Academia Collaboration Platform, MiaoZhen Academy of Marketing Science, in partnership with the Global Digital Marketing Summit (GDMS) and the M360, jointly released the "2024 China Digital Marketing Trends Report".
  • In line with the overall marketing growth rate, the expected growth rate for social media marketing in China in 2024 has also declined to 13%.
  • KOL (Key Opinion Leader) marketing remains a focus of social media investment, with 71% of advertisers indicating their intention to engage in KOL marketing.
  • Additionally, 55% of advertisers plan to increase their investment in mobile internet marketing, while 37% plan to increase their investment in outdoor advertising.

Eclipse Fi Raises $1.9 Million to Build the First Decentralized Web3 Launch Hub on Cosmos and Leading L2s

Retrieved on: 
Tuesday, December 26, 2023
Momentum, Crypto, Linea, Plague, Camelot, News, Blockchain, Faculty, TGE, Social media, DEX, KOL, Cryptocurrency

Eclipse is unique from other launchpads in that it is looking to solve the cross-chain user experience and sustainability issues that plague most launchpads.

Key Points: 
  • Eclipse is unique from other launchpads in that it is looking to solve the cross-chain user experience and sustainability issues that plague most launchpads.
  • Eclipse Founder, Simon Chadwick, says, "We have spent nearly two years developing a token launch model that is sustainable and focuses first and foremost on community.
  • The token launch included listings on Astroport, the leading DEX on Cosmos, Neutron, Arbitrum on Camelot DEX, and Gate.io.
  • You can learn more about Eclipse on the company's official social media channels: